Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform
Authors:
Open Access
- 18 May 2022
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-11
Abstract
Access to a comprehensive molecular alteration screening is patchy in Europe and quality of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European screening platform for patients with thoracic malignancies. Here we report the results of almost 4 years of prospective molecular screening of patients with thoracic malignancies, in terms of quality of the program and molecular alterations identified. Patients with thoracic malignancies at any stage of disease were recruited in SPECTAlung, from June 2015 to May 2019, in 7 different countries. Molecular tumour boards were organised monthly to discuss patients’ molecular and clinical profile and possible biomarker-driven treatments, including clinical trial options. FFPE material was collected and analysed for 576 patients with diagnosis of pleural, lung, or thymic malignancies. Ultimately, 539 patients were eligible (93.6%) and 528 patients were assessable (91.7%). The turn-around time for report generation and molecular tumour board was 214 days (median). Targetable molecular alterations were observed in almost 20% of cases, but treatment adaptation was low (3% of patients). SPECTAlung showed the feasibility of a pan-European screening platform. One fifth of the patients had a targetable molecular alteration. Some operational issues were discovered and adapted to improve efficiency.Keywords
This publication has 24 references indexed in Scilit:
- Genome-wide analysis identifies 12 loci influencing human reproductive behaviorNature Genetics, 2016
- The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysisOncotarget, 2016
- MicroRNA-128-3p regulates mitomycin C-induced DNA damage response in lung cancer cells through repressingSPTAN1Oncotarget, 2016
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomasNature Genetics, 2016
- Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON studyCancer Epidemiology, 2015
- Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective studyActa Clinica Belgica, 2014
- Routine implementation of EGFR mutation testing in clinical practice in Flanders: ‘HERMES’ projectActa Clinica Belgica, 2014
- Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the LungJournal of Thoracic Oncology, 2013
- Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomasVirchows Archiv, 2008
- The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusionsCancer, 2002